Licence Deal

Aortech International PLC
20 March 2008

                                                                  20 March 2008


                           AorTech International plc
                          ('AorTech' or the 'Company')


                         Licence signed with InnerPulse
               for cardiac rhythm management device applications


AorTech International plc (AIM:AOR), the biomaterials and medical device
development company, has signed a non-exclusive licence with InnerPulse, Inc. of
Research Triangle Park, NC, to use Aortech's biostable polyurethane material,
Elast-EonTM, in implantable cardiac rhythm management device applications
(cardiac pacemaker leads excluded).


InnerPulse, a privately held developer of a novel platform of pre-clinical stage
implantable cardiac defibrillators and cardiac pacemakers, has selected
Elast-Eon as the optimal coating material for the PICDTM, its first generation
implantable defibrillator device. In return, InnerPulse will provide AorTech
with milestone and volume based payments. Revenues will be modest in the short
term, but are expected to increase significantly as the InnerPulse product
platform completes testing and is commercialised globally. No further financial
details were disclosed.


InnerPulse plans to incorporate the Elast-EonTM material into its products in
2008. Elast-Eon is currently being assessed by a number of additional companies
for a range of other applications including morbid obesity, neurostimulation,
diabetes, women's health and cardiovascular diseases.


Frank Maguire, CEO of Aortech said:


'We are delighted to sign this initial deal with InnerPulse for this cardiac
rhythm management application. InnerPulse is an innovator in this field that
will couple its inventions with the novel characteristics of Elast-Eon to enable
physicians to improve their care to patients worldwide.


'Elast-Eon's versatility is being demonstrated by the increasingly wide range of
applications in which it is being qualified. We anticipate further licences
being signed in due course which will create a steadily growing, long term
revenue stream for the Company.'


                                     -Ends-


For further information please contact:

AorTech International plc                                 Tel: + 1 801 201 4336
Frank Maguire, Chief Executive

Evolution Securities                                      Tel: [phone]
Bobbie Hilliam
Chris Clarke

Hogarth Partnership Limited                               Tel: [phone]
Melanie Toyne-Sewell / Sarah Richardson

AorTech International plc                                 Tel: + 1 801 201 4336
Frank Maguire, Chief Executive

Evolution Securities                                      Tel: [phone]
Bobbie Hilliam
Chris Clarke

Hogarth Partnership Limited                               Tel: [phone]
Melanie Toyne-Sewell / Sarah Richardson

AorTech International plc                                 Tel: + 1 801 201 4336
Frank Maguire, Chief Executive

Evolution Securities                                      Tel: [phone]
Bobbie Hilliam
Chris Clarke

Hogarth Partnership Limited                               Tel: [phone]
Melanie Toyne-Sewell / Sarah Richardson

AorTech International plc                                 Tel: + 1 801 201 4336
Frank Maguire, Chief Executive

Evolution Securities                                      Tel: [phone]
Bobbie Hilliam
Chris Clarke

Hogarth Partnership Limited                               Tel: [phone]
Melanie Toyne-Sewell / Sarah Richardson


Notes to Editors:

About AorTech International plc

Listed on AIM in London, AorTech International plc wholly owns AorTech
Biomaterials based in Melbourne, Australia. AorTech Biomaterials was formed in
July 1997 to commercialise a range of medical grade polyurethanes for medical
implants developed by the Commonwealth Scientific and Industrial Research
Organisation (CSIRO). For further information, visit the website: 
www.aortech.com.


About Inner-Pulse

Founded in 2003, InnerPulse is a privately held, early-stage company pioneering
a novel technology for those patients who have cardiac rhythm disorders. More
information is available at www.innerpulse.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange